Oncology
Can CAR-T first movers keep pace in a rapidly evolving marke...
The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market.
News
ASH: Stem cell transplant study exposes US zip-code lottery
Access to a stem cell transplant in the US - and the chances of surviving it - depends on social and economic factors, finds a new study.
News
MSD gets first positive trial of Keytruda/Lynparza combo
After a string of trial failures, MSD claims a partial win for Keytruda and Lynparza in advanced epithelial ovarian cancer.
News
ASH: Blenrep ups survival by 42% in multiple myeloma trial
GSK reveals the survival data that it reckons could return BCMA drug Blenrep to the forefront of multiple myeloma treatment.
News
ASH: MSD’s ROR1 drug hits the target in first-line lymphoma
The results of a phase 2 trial of MSD’s anti-ROR1 ADC zilovertamab vedotin back up the company's decision to start a phase 3 trial in DLBCL.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
